Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bimekizumab add-on to methotrexate in moderate to severe rheumatoid arthritis
2016-000393-37Phase 2Completed
- Sponsor
- UCB
- Start
- Jun 2016
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in rheumatoid arthritis (RA) comparing Bimekizumab + methotrexate with Placebo + methotrexate (2 arms). Primary endpoint: ACR50 responders at Week 12. Started Jun 2016; status: completed.
02
Drugs
bimekizumab
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on 2016-000393-37.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-000393-37.